Skip to search formSkip to main contentSkip to account menu

ABT-263

Known as: BcI-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT 263 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

navitoclax

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
Senescence is a cellular defense mechanism that helps cells prevent acquired damage, but chronic senescence, as in aging, can… 
Highly Cited
2017
Highly Cited
2017
DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age
Age‐related bone loss in mice results from a decrease in bone formation and an increase in cortical bone resorption. The former… 
Highly Cited
2014
Highly Cited
2014
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
ObjectiveNavitoclax is a first-in-class, orally bioavailable, targeted Bcl-2 family protein inhibitor and promotes apoptosis… 
Highly Cited
2013
Highly Cited
2013
Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263
Apigenin is an edible plant-derived flavonoid that shows modest antitumor activities in vitro and in vivo. Apigenin treatment… 
Review
2013
Review
2013
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Highly Cited
2012
Highly Cited
2012
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising… 
Highly Cited
2012
Highly Cited
2012
Protein–protein interaction inhibitors get into the groove
Drug developers are getting closer to tapping an unmined gold reserve of protein–protein interaction targets. 
Highly Cited
2011
Highly Cited
2011
Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Combining microtubule-targeting antimitotic drugs with targeted apoptosis potentiators is a promising new chemotherapeutic… 
Highly Cited
2010
Highly Cited
2010
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
PurposeThis study was designed to test the ability of the Bcl-2 family inhibitor ABT-263 to potentiate commonly used… 
Highly Cited
2008
Highly Cited
2008
Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program
ABT‐263 is a potent (Ki < 1 nM) small‐molecule BH3 mimetic that inhibits the antiapoptotic proteins Bcl‐2, Bcl‐xL and Bcl‐w. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)